Frances McMullan, MD
Ophthalmology · Atlanta, GANPI 1629030077
Payments from drug & device makers
Across 34 payments — averaging $61.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Eyepoint US, Inc.$378
- Alcon$291
- AbbVie$187
- Genentech USA, Inc.$150
- Sight Sciences, Inc.$147
- Glaukos Corporation$146
- plus $808 from 11 others
What the payments were for
- Food & beverage$1,95993%
- Education$1296%
- Gifts$171%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Eyepoint US, Inc. | 3 | $378 |
| Alcon | 6 | $291 |
| AbbVie | 9 | $187 |
| Genentech USA, Inc. | 1 | $150 |
| Sight Sciences, Inc. | 1 | $147 |
| Glaukos Corporation | 1 | $146 |
| Biotissue Holdings Inc. | 1 | $144 |
| Alimera Sciences, Inc. | 1 | $127 |
| Rxsight Inc | 1 | $125 |
| Dompe US, Inc. | 1 | $125 |
| Aerie Pharmaceuticals, Inc. | 1 | $119 |
| Novartis | 3 | $69 |
| Sun Pharmaceutical Industries Inc. | 1 | $33 |
| Johnson & Johnson Surgical Vision, Inc. | 1 | $18 |
| Carl Zeiss Meditec, Inc. | 1 | $17 |
| Shire North American Group Inc | 1 | $17 |
| Kala Pharmaceuticals, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- DEXYCU$250
- ILUX$155
- SUSVIMO$150
- OMNI(R) SURGICAL SYSTEM (US)$147
- Prokera$144
- AmnioGraft$144
- YUTIQ$128
- Iluvien$127
- LIGHT ADJUSTABLE LENS (LAL) AND LIGHT DELIVERY DEVICE (LDD)$125
- Oxervate$125
- Rhopressa$119
- Rocklatan$119
How this compares
$2,105 in reported general payments places this provider in the 50th percentile of 481 ophthalmology providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 12 | $2,906 |
| Prednisolone Acetate | 45 | $2,607 |
| Latanoprost | 131 | $2,445 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 59 | $2,174 |
| Brinzolamide | 11 | $1,642 |
| Brimonidine Tartrate | 26 | $1,228 |
| Ketorolac Tromethamine | 31 | $1,143 |
| Polymyxin B Sul-TrimethoprimPolymyxin B Sulf/Trimethoprim | 18 | $244 |
Paid to pharmacies, not to this prescriber.
Other ophthalmology in Atlanta
- Douglas DayAtlanta$1.1M
- Thomas AabergAtlanta$959K
- Gagan SawhneyAtlanta$874K
- Lawrence WoodardAtlanta$578K
- Stephanie VanderveldtAtlanta$384K
- Steven YehAtlanta$289K
- Atul SharmaAtlanta$193K
- Chris BergstromAtlanta$139K
- Anastasios CostaridesAtlanta$137K
- Evan SchoenbergAtlanta$130K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.